North America Antibody Drug Conjugates Market - Forecasts from 2022 to 2027

Antibody Drug Conjugates, or ADCs for short, are a class of biological drugs designed as a targeted therapy for treating cancer. Antibody-drug conjugates provide sensitive differentiation between healthy and diseased tissue by combining the specific targeting of monoclonal antibodies with the cancer-killing capacity of cytotoxic medicines. ADC is a three-component system: cytotoxin anticancer agent, linker, and antibody. A potent cytotoxin anticancer agent is linked with a biodegradable linker to an antibody to make ADCs. The antibody attaches to certain markers on the cancer cell's surface (antigens or receptors). Within the cancer cell, the entire antibody-drug conjugate is internalized, where the linker is degraded and the active drug is liberated.

Market Drivers

The rising prevalence of cancer is the primary driver of the antibody drug conjugates market in North America. Because cancer claims millions of lives each year and is on the rise, the need for an effective treatment is greater than ever. Furthermore, rising health awareness among individuals aids in the early detection of cancer. Which can be treated promptly to prevent cancer from spreading to other regions of the body. Another aspect driving demand in the region is solid health facilities and the availability of cancer treatment.

Furthermore, the region’s growing trend towards cancer therapies, as well as active research and development, is driving the market. in addition, increased R&D in ADCs and rising healthcare expenditure on cancer therapy play a significant role in the market.

Growth Factors

Patients with Cancer Are Increasing

Cancer is the second leading cause of death in North America. Cancer is expected to kill 9.6 million people globally in 2018, according to the World Health Organization. In the USA, 1.7 million new cases of cancer were reported in the year 2018, according to the U.S. Centers for Disease Control and Prevention. The Canadian Cancer Society observed an increase in the number of cases in Canada over the past few years. Cancer is the leading cause of death in Canada, accounting for 28.2% of all deaths. On average, every day 232 Canadians die due to cancer. Further, the organization estimates that there will be 229,200 new cancer cases in Canada and 84,600 cancer deaths in 2021. Lung cancer, breast cancer, prostate cancer, and colon and rectum cancer are the most common types of cancer found in the region. In recent years, in the USA, the new cases of breast cancer have increased prominently. In every n 100,000 people, there are 126.8 new cases of breast cancer. whereas lung and bronchus cancer are the leading causes of the cancer death. In Canada, among females, a high number of breast cancer cases have been reported. An increase in the number of prostate cancers have been observed amongst males. According to the World Health Organization, 21.7% of the new cases were reported to be of breast cancer, whereas 20.7% of new cases in men were reported to be of prostate cancer.

With increasing awareness of cancer and rising, medical facility detection of cancer in its early-stages and early detection helps eliminate it before some serious damage is done. An increasing sedentary lifestyle, increasing consumption of junk food, tobacco and alcohol are some of the prevalent factors causing cancer. Tobacco and alcohol usage, obesity, a lack of fruits and vegetables, and a lack of physical activity are all linked to cancer fatalities.

Global R&D on ADCs is expanding.

With the increasing development in research and development by various companies to find an effective treatment for cancer, more and more companies are investing in R & D to develop such drugs. With deeper understanding and the advent of new technology, the scope of R & D in ADCs has further increased. Moreover, the approval rate for U.S. Food and Drug Association (FDA) products has increased significantly. in the year 2021, 12 ADC drugs have been approved. Further, deep research on interactions between ADCs and the immune system for potential synergistic therapeutic effects that can be used to improve the drug is taking place.

Restraint

Expensive Treatment

Cancer treatments come with a hefty price tag., due to extensive research, licensing, patents, and manufacturing costs of drugs. According to the World Health Organization (WHO), the total annual economic cost of cancer in 2010 was estimated at US$ 1.16 trillion. Antibody-drug conjugates can be an expensive treatment for cancer patients, with a high level of time and money invested in R & D adding to the cost. ADCs also have a high manufacturing cost, which adds up to the final cast. The dominant cost in the manufacturing process of raw material is depending on the nature of the toxins, the drug-linker raw material can cost between $200-$2000 per gram. Furthermore, a small batch of doses produced per year is not able to reach the economies of scale. Further, strict regulation from medical and drug authorities adds to the cost.

The Impact of COVID-19 on the North American Antibody Drug Conjugate Market

The coronavirus pandemic impacted the global antibody drug conjugate market . With the outbreak of the virus and restrictions, non-essential surgeries were avoided by both hospitals/ clinics and patients in fear of the spread of the virus. Several strict restrictions and international restrictions on exports and imports affect the supply chain of raw materials and delivery of medicine itself.

Segmentation:

By Product Type

• Adcetris
• Kadcyla
• Other Product Types

By Application

• Breast Cancer
• Blood Cancer
• Ovarian Cancer
• Lung Cancer
• Brain Tumor
• Others

By End-User

• Hospitals
• Clinics
• Others

By Country

• USA
• Canada
• Mexico